Vimarsana
Biggest News Aggregation in the World

Page 50 - Immunization Practices News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunization Practices. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunization Practices Today - Breaking & Trending Today

CDC advisory panel OKs Pfizer's 5 in 1 meningitis vaccine - Vimarsana News

CDC advisory panel OKs Pfizer's 5 in 1 meningitis vaccine

FDA has granted Pfizer's meningitis vaccine full approval and the CDC Advisory Committee on Immunization Practices has recommended it for use.

CDC advisors vote to recommend routine use of the mpox vaccine to protect people at high risk of infection - Vimarsana News

CDC advisors vote to recommend routine use of the mpox vaccine to protect people at high risk of infection

Men who have sex with men and others who are at high risk of mpox infection should get two doses of the Jynneos vaccine, even now that the recent public health emergency in the United States has passed, according to an independent panel of experts that advises the US Centers for Disease Control and Prevention on its vaccine decisions.

Source: aol.com
ACIP Votes for Routine Use of Jynneos in Adults at Risk of Mpox Infection - Vimarsana News

ACIP Votes for Routine Use of Jynneos in Adults at Risk of Mpox Infection

The CDC’s Advisory Committee on Immunization Practices has voted in favor of routine use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for the prevention of mpox disease.

Source: empr.com
GSK's Arexvy shows positive preliminary results from phase III trial - Vimarsana News

GSK's Arexvy shows positive preliminary results from phase III trial

GSK's Arexvy shows positive preliminary results from phase III trial

RSV vaccine could help protect some adults as young as 50, drugmaker says - Vimarsana News

RSV vaccine could help protect some adults as young as 50, drugmaker says

An RSV vaccine approved for use in older adults could help protect people as young as 50 who have certain underlying medical conditions and are at increased risk from the respiratory virus, according to preliminary data released by vaccine maker GSK.

Source: cnn.com